Rituximab for refractory autoimmune hepatitis: A case report

Auto-immune hepatitis (AIH) is a chronic progressive hepatitis of unknown aetiology whose clinical presentation ranges from asymptomatic to fulminant hepatic failure. Corticosteroids and azathioprine, which are considered standard therapy for AIH, may, however, be associated with treatment failures...

Full description

Saved in:
Bibliographic Details
Published in:Arab journal of gastroenterology 2013-09, Vol.14 (3), p.135-138
Main Authors: Al-Busafi, Said A., Michel, René P., Deschenes, Marc
Format: Article
Language:English
Subjects:
Aged
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Auto-immune
Female
Hepatitis
Hepatitis, Autoimmune - drug therapy
Hepatitis, Autoimmune - pathology
Humans
Immunologic Factors - therapeutic use
Prednisone - therapeutic use
Rituximab
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Auto-immune hepatitis (AIH) is a chronic progressive hepatitis of unknown aetiology whose clinical presentation ranges from asymptomatic to fulminant hepatic failure. Corticosteroids and azathioprine, which are considered standard therapy for AIH, may, however, be associated with treatment failures and toxicities. Among the alternative medications under investigation, rituximab, used to treat successfully various auto-immune disorders, has fewer side effects. We report herein the case of a 68-year-old woman who developed AIH with worsening clinical, laboratory and histological features despite high-dose prednisone. On rituximab, the patient showed rapid and dramatic clinical improvement, suggesting a therapeutic role for this medication in severe AIH. Indeed, prospective controlled studies are needed to assess and validate this role.
ISSN:1687-1979
2090-2387
DOI:10.1016/j.ajg.2013.08.009